AstraZeneca Stock Falls While BMY Stock Jumps on Merger Talks
BMY stock climbed while AstraZeneca stock dropped after reports of merger talks that could create a nearly $400 billion drugmaker.
Opent in een nieuw tabblad. Via Cryptopage meten we de klik voor statistieken.
Partner